First Trust Advisors LP Has $1.33 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

First Trust Advisors LP lifted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 260.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,442 shares of the company's stock after acquiring an additional 47,308 shares during the period. First Trust Advisors LP's holdings in Denali Therapeutics were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in DNLI. Rhumbline Advisers grew its position in Denali Therapeutics by 0.3% during the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock worth $3,880,000 after purchasing an additional 497 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares during the period. Sterling Capital Management LLC raised its position in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the period. E Fund Management Co. Ltd. lifted its stake in Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after acquiring an additional 2,436 shares in the last quarter. Finally, KBC Group NV grew its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DNLI. HC Wainwright decreased their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday. Robert W. Baird dropped their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday. Wedbush lowered their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday. Oppenheimer cut their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Stock Down 0.3 %

Denali Therapeutics stock traded down $0.04 during trading hours on Friday, hitting $14.39. The stock had a trading volume of 1,367,985 shares, compared to its average volume of 1,090,932. The company has a 50-day moving average of $14.27 and a two-hundred day moving average of $20.08. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The company has a market cap of $2.09 billion, a PE ratio of -5.21 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period in the previous year, the business posted ($0.68) EPS. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.